Format

Send to

Choose Destination
Bone. 2011 Jan;48(1):23-9. doi: 10.1016/j.bone.2010.08.004. Epub 2010 Aug 10.

TGF-β in cancer and bone: implications for treatment of bone metastases.

Author information

1
Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA.

Abstract

Bone metastases are common in patients with advanced breast, prostate and lung cancer. Tumor cells co-opt bone cells to drive a feed-forward cycle which disrupts normal bone remodeling to result in abnormal bone destruction or formation and tumor growth in bone. Transforming growth factor-beta (TGF-β) is a major bone-derived factor, which contributes to this vicious cycle of bone metastasis. TGF-β released from bone matrix during osteoclastic resorption stimulates tumor cells to produce osteolytic factors further increasing bone resorption adjacent to the tumor cells. TGF-β also regulates 1) key components of the metastatic cascade such as epithelial-mesenchymal transition, tumor cell invasion, angiogenesis and immunosuppression as well as 2) normal bone remodeling and coupling of bone resorption and formation. Preclinical models demonstrate that blockade of TGF-β signaling is effective to treat and prevent bone metastases as well as to increase bone mass.

PMID:
20699127
DOI:
10.1016/j.bone.2010.08.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center